CIK 0000315545
- Non-accelerated filer
- Smaller reporting company
PROVECTUS BIOPHARMACEUTICALS, INC.
Sign in to watch- Ticker
- PVCT
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 900031917
- Phone
- +1 866-594-5999
- Business address
- 800 S. GAY STREET, SUITE 1610, KNOXVILLE, TN, 37929
- Former names
- PROVECTUS PHARMACEUTICALS INC, PROVECTUS PHARMACEUTICAL INC, ZAMAGE DIGITAL IMAGING INC, SPM GROUP INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-29 | Pershing Edward Director | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | $50,000.00 | $0 | |
| 2023-11-15 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2023-11-15 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +9,440 | 772,920 | ||
| 2023-11-08 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2023-11-08 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +37,744 | 763,480 | ||
| 2023-11-01 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2023-11-01 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +13,216 | 725,736 | ||
| 2023-10-27 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2023-10-27 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +2,832 | 712,520 | ||
| 2023-10-14 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2023-10-14 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +18,888 | 709,688 | ||
| 2023-10-03 | Pershing Edward Director | Purchase · Series D-1 Convertible Preferred Stock | +19,311 | $2.86 | $55K | 690,800 |
| 2023-09-30 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2023-09-30 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +41,518 | 671,489 | ||
| 2023-09-23 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2023-09-23 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +28,320 | 629,971 | ||
| 2023-09-01 | Pershing Edward Director | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2023-09-01 | Pershing Edward Director | Option exercise · Series D-1 Convertible Preferred Stock | +37,760 | 601,651 | ||
| 2023-08-11 | Morris Jeffrey Allen 10% owner | Grant or award · 8% Secured Convertible Promissory Note | +0 | 244,584 | ||
| 2023-08-03 | Pershing Edward Director | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | $75,000.00 | $0 |
Page 10 of 17 · 329 trades